Alpha Tau Completes IMPACT Pancreatic Cancer Enrollment
Jerusalem, Israel, August 31, 2026 Alpha Tau Medical Ltd. has completed patient enrollment in its multicenter IMPACT (Intratumoral Pancreatic...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Jerusalem, Israel, August 31, 2026 Alpha Tau Medical Ltd. has completed patient enrollment in its multicenter IMPACT (Intratumoral Pancreatic...
The Woodlands, Texas, USA, September 1, 2026 Autonomix Medical, Inc. announced that two scientific abstracts featuring its transvascular nerve-targeting...
Valby, Denmark, September 3, 2026 H. Lundbeck A/S will present new mechanistic and clinical research on bexicaserin (LP352) at...
